Rundu Pharmaceutical (Jingmen) Co., Ltd.
Focusing on high-class production technology and building large-scale production capacity
Rundu (Jingmen) started production in 2021, and is expected to be fully completed in 2025 after the completion of a total construction area of 220,000 square meters, with an annual output of 4,000 tons of APIs and intermediate products.
Rundu Pharmaceutical (Jingmen) Co., Ltd. (Rundu (Jingmen)) is a wholly-owned subsidiary of Zhuhai Rundu Pharmaceutical Co., Ltd. (Rundu Pharma, stock code: 002923).
Founded in 2018, Rundu (Jingmen) Company, located in the Chemical Recycling Industrial Park, High-tech District, Jingmen City, Hubei Province, is a production base of high-class APIs (including pharmaceutical intermediates), covering 13 types of chemical APIs and pharmaceutical intermediates, including antihypertensive products, anti-peptic ulcer products, anti-inflammatory and analgesic products, antifungal products, Parkinson's products, cardiovascular disease products, benign prostatic hyperplasia products, hyperphosphatemia products, anesthesia products, etc.
Rundu (Jingmen) company has built a complete quality system, with a laboratory of more than 2,400 square meters, equipped with complete testing instruments for APIs from method validation, testing, stability study, sample retained and other full-process data analysis capabilities.
Rundu (Jingmen) company has 6 API workshops and 10 intermediate workshops, which can meet the production needs of intermediates and APIs from kilograms to tons.
Characteristic API technologies
-
Enzyme-catalyzed reactions, asymmetric synthesis, chiral resolution
Grignard reaction, Ammonia Oxidation reaction, Friedel-Crafts reaction, Curtius rearrangement, Wittig reaction
Hydrogenation, chiral directional hydrogenation
-
Bromination, continuous flow nitration, oxidation, continuous oxidation
Low-temperature, high-temperature organometallic reagent reaction, azide reaction
Qualifications for the use of hazardous materials (sodium azide, sodium cyanide, bromine)
Contact us
-
CMO/CDMO/CRO cooperation: Miss Zhao 13750046510 zhaoning@rdpharma.cn
Stock code002923
